AeroLeads people directory · profile
Dawn Bir Email & Phone Number
Interim President and Chief Executive Officer
at
Geron Corporation
1 work email found
@reatapharma.com
2 phones found area 972 and 408
LinkedIn matched
✓ Verified Jul 2026
4 data sources
Profile completeness 100%
Current company
Role
Interim President and Chief Executive Officer
Location
United States
Who is Dawn Bir? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Dawn Bir is listed as Interim President and Chief Executive Officer at Geron Corporation, based in United States. AeroLeads shows a work email signal at reatapharma.com, phone signal with area code 972, 408, and a matched LinkedIn profile for Dawn Bir.
Dawn Bir previously worked as Member Board of Directors at Soleno Therapeutics, Inc. and Member Board of Directors at Geron Corporation. Dawn Bir holds Bs, Biological Sciences from Binghamton University.
Company email context
Email format at Geron Corporation
This section adds company-level context without repeating Dawn Bir's masked contact details.
{first}.{last}@reatapharma.com
86% confidence
AeroLeads found 1 current-domain work email signal for Dawn Bir. Compare company email patterns before reaching out.
Profile bio
About Dawn Bir
A seasoned development-stage biotechnology leader, C-suite executive and board public biotech board member. Raised capital as a member of the executive team and scaled multiple companies for development and commercial success, leading to multibillion-dollar company acquisitions. Over 30 years of business, operations, development and diverse therapeutic area experience. Broad general management, operational and functional area experience including manufacturing, business development, global commercial, corporate communications, investor relations. Drug development, financing, clinical trial design and execution, regulatory strategy.
Listed skills include Oncology, Pharmaceutical Industry, Product Launch, Pharmaceutical Sales, and 34 others.
Current workplace
Dawn Bir's current company
Company context helps verify the profile and gives searchers a useful next step.
9 roles
Dawn Bir work experience
A career timeline built from the work history available for this profile.
Member Board Of Directors
CurrentSoleno Therapeutics is a public, clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases.
Aug 2024 - Present
Member Board Of Directors
CurrentGeron is a public, late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Mar 2019 - Present
Executive Vice President, Officer, C-Suite Executive
Executive Vice President and member of the core executive team reporting to the CEO of Reata Pharmaceuticals for over 7 years through the company’s $7.3B acquisition by Biogen in September 2023. Reata successfully developed small molecule therapeutics for the treatment of rare and devastating diseases. Dawn was part of a small executive team responsible for early strategic portfolio decisions, clinical trial design and multiple corporate financing efforts, helping to resource development-stage assets. She has broad operational experience, establishing the teams and infrastructure supporting organizational growth from 30 employees to over 300. She served as a member of the joint steering committee governing the company’s corporate international partnership with Japanese development partner, Kiowa-Kirin Corporation. Through her leadership, the strategic and operational plans for the company’s first product launch in the US and globally were developed. She prepared the company for approval, and successfully executed launch and commercialization in 2023.
Sep 2016 - Jan 2024
Vice President Commercial
Vice President Sales, US • Commercial Leadership of Hematology/Oncology organization responsible for IMBRUVICA revenue.o Organization Build: Lead the efforts to establish all needed operations and infrastructure to support commercialization of first product (hematology). • History-Making Hematology Launch: Second commercial year exceeded revenue expectations, generating over $1B in sales (US sales)Company was acquired by AbbVie for $21B in 2015.
Mar 2013 - Sep 2016
Vice President Mckesson Us Pharmaceuticals
SKY Pharmaceuticals & Rx Pak September 2011 to March 2013• National responsibility for 2 companies and revenue centers. Leadership of multiple teams including sales, marketing, contract management, project management and customer service, driving acute care hospital sales.• Profitability and margin management of entire product portfolio (P&L).• Responsible for financial expectations across all revenue centers and managing OPEX to within 3% of plan.• Team and organizational development. Sales force alignment and sizing, compensation plan development.• Lead sales strategy across multiple customer segments including acute care, wholesalers, GPO’s & federal.• Business Development: Acquisition and divestiture.
Oct 2011 - Mar 2013
Area Manager, Oncology, Immunology, Dermatology
Area Manager, Central, US • Therapeutic areas include oncology and hematology, immunology, dermatology• Buy and bill sales model• Built and developed 2 sales teams that consistently lead the nation in performance.• Division of the Year in and 2008 and 2010• Sr. Operations Director, July-December 2008
Jul 2007 - Oct 2011
Area Vice President, Medical-Surgical Sales
Vice President, Sales & Operations, Northeast Lead Hospital Acute Care/Medical-Surgical sales force and operations across 7 state region in the northeast. 3 Distribution centers, Sales Management and Sales support teams.
Sep 2005 - Sep 2007
Multiple Roles With Increasing Scope Of Responsibility
Therapeutic area experience includes Oncology, Dermatology, Cardiovascular, Neuroscience, Metabolic and Anti-infective.
Jul 1997 - Oct 2005
2 education records
Dawn Bir education
Bs, Biological Sciences
Binghamton University
Continuing Executive Education Finance
Columbia Business School
FAQ
Frequently asked questions about Dawn Bir
Quick answers generated from the profile data available on this page.
What company does Dawn Bir work for?
Dawn Bir works for Geron Corporation.
What is Dawn Bir's role at Geron Corporation?
Dawn Bir is listed as Interim President and Chief Executive Officer at Geron Corporation.
What is Dawn Bir's email address?
AeroLeads has found 1 work email signal at @reatapharma.com for Dawn Bir at Geron Corporation.
What is Dawn Bir's phone number?
AeroLeads has found 2 phone signal(s) with area code 972, 408 for Dawn Bir at Geron Corporation.
Where is Dawn Bir based?
Dawn Bir is based in United States while working with Geron Corporation.
What companies has Dawn Bir worked for?
Dawn Bir has worked for Geron Corporation, Soleno Therapeutics, Inc., Reata Pharmaceuticals, Inc., Pharmacyclics, and Mckesson.
How can I contact Dawn Bir?
You can use AeroLeads to view verified contact signals for Dawn Bir at Geron Corporation, including work email, phone, and LinkedIn data when available.
What schools did Dawn Bir attend?
Dawn Bir holds Bs, Biological Sciences from Binghamton University.
What skills is Dawn Bir known for?
Dawn Bir is listed with skills including Oncology, Pharmaceutical Industry, Product Launch, Pharmaceutical Sales, Commercialization, Dermatology, Cardiology, and Biotechnology.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial